DNLI Denali Therapeutics Inc.
Healthcare$19.38+3.97%ClosedMarket Cap: $3.08B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.76
P/S
0.00
EV/EBITDA
-4.98
DCF Value
$0.92
FCF Yield
-14.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-52.2%
ROA
-40.1%
ROIC
-46.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-137.4M | $-128.4M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-137.4M | $-128.5M | $— | — |
| FY null | $0.00 | -Infinity% | $-555.3M | $-512.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-137.4M | $-126.9M | $— | — |
| Q2 null | $0.00 | NaN% | $-135.0M | $-124.1M | $— | — |
| Q1 null | $0.00 | NaN% | $-145.6M | $-133.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-129.8M | $-114.8M | $— | — |
| FY null | $0.00 | NaN% | $-487.3M | $-422.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-123.2M | $-107.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-116.6M | $-99.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-117.7M | $-101.8M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-132.6M | $-119.5M | $-0.86 | — |